Clinical Trial Update: The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents [Phase 2]

View source ↗

Summary

Phase 2 trial assessing certolizumab pegol for active Crohn's disease in children and adolescents was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Celltech | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED | Results posted: 2013-11-21